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Constructing a Georgia Surveillance System for Hemoglobinopathies Using 
Multiple Data Sets: The First Step towards a Comprehensive Prevention and Service Delivery Strategy 
Angela Snyder, Ph.D., M.P.H ; Mei Zhou, M.S.;  Jane Branscomb, M.P.H*
RESEARCH OBJECTIVE
To construct a hemoglobinopathy surveillance system to determine the annual 
incidence and ve-year prevalence (2004-2008) of hemoglobinopathies in Georgia 
and to describe the demographics of the populations living with these disorders. 
STUDY DESIGN
The surveillance system of hemoglobinopathy combines data from ve data 
sources: (1)State Newborn Screening Program (NBS); (2)Georgia hospital discharge 
le, including most in-patient and emergency room visits in the state; (3) Grady, 
CHOA and GHSU health systems, including all outpatient visits; (4) State Medicaid 
and CHIP programs; and (5) State Health Benet Plan (SHBP).  Laboratory screening 
and conrmatory results, coupled with clinical expertise, are used to conrm cases 
from NBS, Grady, CHOA and GHSU data. ICD-9, CPT and NDC codes are used to 
identify probable and possible cases from additional administrative datasets. 
A probabilistic matching method is adopted to merge all datasets and remove 
duplicate records.  Each data source contains dierent data elements that can be 
used to link the records. Variables used in linking include but are not limited to 
patient’s name, date of birth, sex, county, zip code, mother’s name, phone number, 
and address. Records are compared on each of the specied variables and a weight 
is generated for each potential match to reect the strength of agreement. 
POPULATION STUDIED
Individuals with clinical or laboratory indication of sickle cell disease who lived in 
Georgia between 2004 and 2008.
PRINCIPAL FINDINGS
From 2004 through 2008, 829 newborns screened positive for a sickle cell disorder 
in Georgia with 85 percent of them having a conrmed diagnosis (Figure 1).  Slightly 
over half of the newborns were diagnosed with SS or S Beta Zero Thalassemia and 
about one quarter Sickle C disease.  Using newborn screening data from 2004 
through 2008 (Figure 2), we identied the counties with the highest number of 
incident cases.  Most cases are found in the ve metro Atlanta counties (Fulton, 
DeKalb, Cobb, Gwinnett and Clayton) as well as the smaller metropolitan areas in 
South and Southeastern Georgia.  
Figure 1: Incident cases of sickle cell disease by genotype
Figure 2: Georgia newborns screening positive for sickle cell 
disease, January 2004 through December 2008
During that same time period, CHOA treated approximately 1,490 pediatric patients 
with a hemoglobin disorder, and Grady and GHSU treated approximately 1,674 and 
1,256 patients, respectively.  Medicaid and CHIP programs paid claims for 
approximately 14,667 enrollees with a hemoglobinopathy-associated medical 
encounter, while the SHBP covered such services for 1,474 enrollees. Lastly, close to 
10,097 individuals were treated in a Georgia emergency room or hospital for a 
hemoglobinopathy (Figure 3).  
Figure 3:  Overlap between health insurance claims data and 
Georgia hospital discharge data
We nd 4,443 unique individuals (1,795 adults and 2,646 children) treated for a 
hemoglobinopathy in Georgia from 2004 through 2008 when merging all clinical and 
NBS data.  More than 97 percent of these individuals have a conrmed diagnosis.  We nd 
20,939 possible cases when merging the administrative datasets:  Medicaid, SHBP, and 
Hospital discharge data with 36 percent of the Medicaid members overlapping with the 
hospital discharge le and 52 percent of the individuals identied through hospital 
discharge data overlapping with Medicaid.  Twenty-one percent of the SHBP members 
were also found in the Hospital discharge le.  While the next step is to merge and 
deduplicate the clinical and administrative data sets, we estimate that up to 47 percent of 
the individuals identied through state hospital discharge data may also be present in 
one of the three clinical systems.  
CONCLUSIONS
The new surveillance system of hemoglobinopathies provides rst hand estimates of the 
prevalence and geographic prole of the diseased population in Georgia. It can also be 
exploited to test the validity of using administrative data for health services research of 
sickle cell disease.  This type of surveillance system is essential for the Georgia 
Department of Public Health to craft an eective service delivery strategy to a targeted 
population and prevent associated complications and healthcare utilization which may 
arise from unmanaged disease.
IMPLICATIONS FOR POLICY, DELIVERY OR 
PRACTICE
Early outcomes from this project have allowed us to identify areas to focus 
hemoglobinopathy prevention and outreach eorts. Further progress will allow us to 
answer programmatic, policy, and research questions specic to Georgia, and aid in the 
development of educational materials for providers, policy-makers and legislators. 
Lessons learned can be shared with other states interested in developing similar 
surveillance systems and shared with the health services research community who 
typically use administrative data for epidemiologic research.  
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